Invitrogen Closes $210M Sale of BioReliance to Avista Capital

Apr 13, 2007

NEW YORK (GenomeWeb News) - Invitrogen has closed the $210 million sale of its BioReliance unit to Avista Capital Partners as part of its plans to better organize some of its acquisitions and streamline its focus, the company said today.

As GenomeWeb Daily News reported on Feb. 14, Invitrogen’s CEO and chairman Greg Lucier agreed to sell the biological services unit to Avista in an effort to focus on its platform of scientific technologies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Getting It Early

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

Food Bugs to Meet Sequencers

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

From Ancient Bathrooms

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

This Week in Nature

In Nature this week: ash dieback disease fungal genome, and more.

Main menu